Regeneron announced FDA approval for Livsayis, its new siRNA therapy for generalized myasthenia gravis. This marks a significant milestone as it's Regeneron's first siRNA and neurology drug, offering a new, less frequent dosing option for patients.
Regeneron Pharmaceuticals received FDA approval for Livsayis (cemdisiran) to treat generalized myasthenia gravis (gMG) in adult patients. This is a significant event for Regeneron as it represents their first approved siRNA therapy and their entry into the neurology market. The drug's unique quarterly subcutaneous dosing frequency could be a competitive advantage, potentially capturing market share from existing treatments. This approval is a positive catalyst for REGN, offering a new revenue stream and diversifying its portfolio. Competitors in the gMG space, such as Alexion (AstraZeneca) with Soliris/Ultomiris and UCB with Rystiggo/Zilbrysq, may face increased competitive pressure, potentially impacting their future sales in this indication. Short-term, REGN could see a positive stock reaction, while long-term implications depend on Livsayis's market adoption and commercial success.